Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus

European Journal of Endocrinology

Volumn 171, Issue 3, 2014, Pages 293-300

  Catalano, Antonino ^a   Pintaudi, Basilio ^b   Morabito, Nancy ^a   Di Vieste, Giacoma ^a   Giunta, Loretta ^a   Lucia Bruno, Maria ^a   Cucinotta, Domenico ^a   Lasco, Antonino ^a   Di Benedetto, Antonino ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BETA CATENIN; CYANOCOBALAMIN; DEOXYPYRIDINOLINE; HOMOCYSTEINE; HYDROXYPROLINE; PYRIDINOLINE; SCLEROSTIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; SOST PROTEIN, HUMAN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CAUCASIAN; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL RESEARCH; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; ULTRASOUND; VASCULAR DISEASE; WNT SIGNALING PATHWAY; BLOOD; COHORT ANALYSIS; GENETIC MARKER; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC MARKERS; HUMANS; MALE; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84907210433     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0106     Document Type: Article

References (40)

1. Hofbauer LC, Brueck CC, Singh SK & Dobnig H. Osteoporosis in patients with diabetes mellitus. Journal of Bone and Mineral Research 2007 22 1317-1328. (doi:10.1359/jbmr.070510)
2. Rakel A, Sheehy O, Rahme E & LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes & Metabolism 2008 34 193-205. (doi:10.1016/j.diabet.2007.10.008)
3. Danielson KK, Elliott ME, LeCaire T, Binkley N& Palta M. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporosis International 2009 20 923-933. (doi:10.1007/s00198-008-0763-3)
4. MacDonald BT, Tamai K & He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Developmental Cell 2009 17 9-26. (doi:10.1016/j.devcel.2009.06.016)
5. Nelson WJ & Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004 303 1483-1487. (doi:10.1126/science.1094291)
6. Moon RT, Kohn AD, De Ferrari GV & Kaykas A. Wnt and β-catenin signaling: diseases and therapies. Nature Reviews. Genetics 2004 5 691-701. (doi:10.1038/nrg1427)
7. Mill C, Tsaousi A, Woodward E, Johnson J & George S. Increased expression of Wnt5A in unstable atherosclerotic plaques is associated with increased MMP expression and may contribute to instability. Atherosclerosis 2010 213 E12. (doi:10.1016/j.atherosclerosis.2010. 08.022)
8. Mill C & George SJ. Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. Cardiovascular Research 2012 95 233-240. (doi:10.1093/cvr/cvs141)
9. Tsaousi A, Williams H, Lyon CA, Taylor V, Swain A, Johnson JL & George SJ. Wnt4/b-catenin signalling induces VSMC proliferation and is associated with intimal thickening. Circulation Research 2011 108 427-436. (doi:10.1161/CIRCRESAHA.110.233999)
10. Christman MA II, Goetz DJ, Dickerson E, McCall KD, Lewis CJ, Benencia F, Silver MJ, Kohn LD & Malgor R. Wnt5a is expressed in murine and human atherosclerotic lesions. American Journal of Physiology. Heart and Circulatory Physiology 2008 294 H2864-H2870. (doi:10.1152/ajpheart.00982.2007)
11. Moester MJC, Papapoulos SE, LowikCW& van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcified Tissue International 2010 87 99-107. (doi:10.1007/s00223-010-9372-1)
12. Shao JS, Aly ZA, Lai CF, Cheng SL, Cai J, Huang E, Behrmann A & Towler DA. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Annals of the New York Academy of Sciences 2007 1117 40-50. (doi:10.1196/annals.1402.075)
13. Zhu D, Mackenzie NC, Millan JL, Farquharson C & MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE 2011 6 e19595. (doi:10.1371/journal.pone.0019595)
14. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M & Mayr M. Proteomics characterization of extracellular space components in the human aorta. Molecular & Cellular Proteomics 2010 9 2048-2062. (doi:10.1074/mcp.M110.001693)
15. Anderson JB, Barnett E & Nordin BE. The relation between osteoporosis and aortic calcification. British Journal of Radiology 1964 37 910-912. (doi:10.1259/0007-1285-37-444-910)
16. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2012 97 1737-1744. (doi:10.1210/jc.2011-2958)
17. Neumann T, Hofbauer LC, Rauner M, Lodes S, Kästner B, Franke S, Kiehntopf M, Lehmann T, Müller UA, Wolf G et al. Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. Clinical Endocrinology 2014 80 649-655. (doi:10.1111/cen.12364)
18. Perk J, DeBacker G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Heart Journal 2012 33 1635-1701. (doi:10.1093/eurheartj/ehs092)
19. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2013 36 S11-S66. (doi:10.2337/dc13-S011)
20. Catalano A, Morabito N, Di Vieste G, Pintaudi B, Cucinotta D, Lasco A & Di Benedetto A. Phalangeal quantitative ultrasound and metabolic control in pre-menopausal women with type 1 diabetes mellitus. Journal of Endocrinological Investigation 2013 36 347-351. (doi:10.3275/8646)
21. Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 2005 8 751-764. (doi:10.1016/j.devcel.2005. 02.017)
22. Lombardi G, Lanteri P, Colombini A, Mariotti M & Banfi G. Sclerostin concentrations in athletes: role of load and gender. Journal of Biological Regulators and Homeostatic Agents 2012 26 157-163.
23. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ III & Khosla S. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. Journal of Bone and Mineral Research 2011 26 373-379. (doi:10.1002/jbmr.217)
24. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR & Fahrleitner-Pammer A. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. Journal of Clinical Endocrinology and metabolism 2012 97 148-154. (doi:10.1210/jc.2011-2152)
25. Mirza FS, Padhi ID, Raisz LG & Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2010 95 1991-1997. (doi:10.1210/jc.2009-2283)
26. García-Fontana B, Morales-Santana S, Varsavsky M, García-Martín A, García-Salcedo JA, Reyes-García R & Muñoz-Torres M. Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporosis International 2014 25 645-651.
27. Codner E, Merino PM & Tena-Sempere M. Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Human Reproduction Update 2012 18 568-585. (doi:10.1093/humupd/dms024)
28. Tomar R, Dhindsa S, Chaudhuri A, Mohanty P, Garg R & Dandona P. Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care 2006 29 1120-1122. (doi:10.2337/dc06-0197)
29. van Dam EW, Dekker JM, Lentjes EG, Romijn FP, Smulders YM, PostWJ, Romijn JA & Krans HM. Steroids in adult men with type 1 diabetes: a tendency to hypogonadism. Diabetes Care 2003 26 1812-1818. (doi:10.2337/diacare.26.6.1812)
30. Morales-Santana S, García-Fontana B, García-Martín A, Rozas- Moreno P, García-Salcedo JA, Reyes-García R & Muñoz-Torres M. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013 36 1667-1674. (doi:10.2337/dc12-1691)
31. Szulc P, Bertholon C, Borel O, Marchand F & Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. Journal of Bone and Mineral Research 2013 28 855-864. (doi:10.1002/jbmr.1823)
32. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH & Mousa SA. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. Journal of Bone and Mineral Research 2012 27 2592-2602. (doi:10.1002/jbmr.1718)
33. YamamotoM, YamauchiM& Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2013 98 4030-4037. (doi:10.1210/jc.2013-2143)
34. Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I & Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1 (DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 2013 56 42-47. (doi:10.1016/j.bone.2013.05.010)
35. Claes KJ, Viaene L, Heye S, Meijers B, d'Haese P & Evenepoel P. Sclerostin: another vascular calcification inhibitor? Journal of Clinical Endocrinology and Metabolism 2013 98 3221-3228. (doi:10.1210/jc. 2013-1521)
36. Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P & D'Haese PC. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrology, Dialysis, Transplantation 2013 28 3024-3030. (doi:10.1093/ndt/gft039)
37. Shao JS, Cai J & Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 1423-1430. (doi:10.1161/01.ATV. 0000220441.42041.20)
38. Djaberi R, Schuijf JD, Boersma E, Kroft LJ, Pereira AM, Romijn JA, Scholte AJ, Jukema JW & Bax JJ. Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as assessed by multislice computed tomography. Diabetes Care 2009 32 1507-1512. (doi:10.2337/dc09-0320)
39. Funato Y, Michiue T, Asashima M & Miki H. The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-b-catenin signalling through dishevelled. Nature Cell Biology 2006 8 501-508. (doi:10.1038/ncb1405)
40. Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R & Fiore CE. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Diabetes & Vascular Disease Research 2014 11 48-52. (doi:10.1177/1479164113510923)